Takehiko Sakai1,2, Enver Ozkurt1,2, Stephen DeSantis2, Stephanie M Wong1,3, Laurel Rosenbaum1, Hui Zheng4, Mehra Golshan5,6. 1. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 2. Breast Oncology Program, Dana Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02115, USA. 3. McGill University Health Centre, Montreal, QC, Canada. 4. Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA. 5. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. mgolshan@bwh.harvard.edu. 6. Breast Oncology Program, Dana Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02115, USA. mgolshan@bwh.harvard.edu.
Abstract
PURPOSE: Increase in breast cancer survivorship, advancements in diagnostic imaging and standardization of contralateral breast screening before breast cancer surgery have resulted in increased detection of contralateral breast cancer (CBC). The aim of this study was to assess national trends of synchronous bilateral breast cancer (sBBC) and metachronous bilateral breast cancer (mBBC) incidence in newly diagnosed breast cancer patients. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1973-2014) was used to identify 11,177 women diagnosed with CBC. CBC was classified as sBBC when primary breast cancer in both breasts is diagnosed in the same year, or as mBBC, when diagnosed more than one year from primary breast cancer. Temporal trends in sBBC incidence were then evaluated using the Cochran-Armitage test for trend. RESULTS: Of the 11,177 women diagnosed with CBC, 4228 (38%) had sBBC and 6949 (62%) had mBBC. The incidence of sBBC increased significantly from 1.4% in 1975 to 2.9% in 2014 (p < 0.001). sBBC was more likely to be diagnosed as early stage in recent years (78% in 1975 vs. 90% in 2014 [p < 0.001]), and 69% of patients were treated with mastectomy in 2014. CONCLUSION: The number of sBBC has increased, and contralateral tumors are more likely to be detected at an early stage with the first primary breast cancer. Despite the early stage findings, most were treated with mastectomy. Further studies are needed to define the best therapy for patients with contralateral disease and optimal surveillance and detection methods.
PURPOSE: Increase in breast cancer survivorship, advancements in diagnostic imaging and standardization of contralateral breast screening before breast cancer surgery have resulted in increased detection of contralateral breast cancer (CBC). The aim of this study was to assess national trends of synchronous bilateral breast cancer (sBBC) and metachronous bilateral breast cancer (mBBC) incidence in newly diagnosed breast cancerpatients. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (1973-2014) was used to identify 11,177 women diagnosed with CBC. CBC was classified as sBBC when primary breast cancer in both breasts is diagnosed in the same year, or as mBBC, when diagnosed more than one year from primary breast cancer. Temporal trends in sBBC incidence were then evaluated using the Cochran-Armitage test for trend. RESULTS: Of the 11,177 women diagnosed with CBC, 4228 (38%) had sBBC and 6949 (62%) had mBBC. The incidence of sBBC increased significantly from 1.4% in 1975 to 2.9% in 2014 (p < 0.001). sBBC was more likely to be diagnosed as early stage in recent years (78% in 1975 vs. 90% in 2014 [p < 0.001]), and 69% of patients were treated with mastectomy in 2014. CONCLUSION: The number of sBBC has increased, and contralateral tumors are more likely to be detected at an early stage with the first primary breast cancer. Despite the early stage findings, most were treated with mastectomy. Further studies are needed to define the best therapy for patients with contralateral disease and optimal surveillance and detection methods.
Entities:
Keywords:
Bilateral breast cancer; Incidence; Metachronous; SEER; Synchronous; Trends
Authors: Melissa Anne Mallory; Karissa Whiting; Anna Park; Mithat Gönen; Elizabeth Gilbert; Tari A King; Melissa L Pilewskie Journal: Breast Cancer Res Treat Date: 2022-04-29 Impact factor: 4.872
Authors: Nita H Mukand; Naomi Y Ko; Nadia A Nabulsi; Colin C Hubbard; Brian C-H Chiu; Kent F Hoskins; Gregory S Calip Journal: Breast Cancer Date: 2021-11-19 Impact factor: 4.239
Authors: D Brock Hewitt; Yaming Li; Oindrila Bhattacharyya; James L Fisher; Daniel Stover; Samilia Obeng-Gyasi Journal: J Racial Ethn Health Disparities Date: 2022-04-06
Authors: Linda M Pak; Rachel Gaither; Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Jeffrey Peppercorn; Lidia Schapira; Virginia F Borges; Steven E Come; Ellen Warner; Craig Snow; Laura C Collins; Tari A King; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2020-11-26 Impact factor: 4.872